PASADENA, Calif.--(BUSINESS WIRE)--Feb. 9, 2006--Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (Nasdaq:ARWR), announced today that it has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its lead anti-cancer compound, IT-101, a combination of its patented polymer technology, Cyclosert(TM), and the anti-cancer compound camptothecin, to treat patients with unresectable or metastatic solid tumors. The objectives of the Phase I clinical protocol submitted with the IND are to evaluate the safety, pharmacokinetics and tolerability of IT-101 in humans.
